Skip to main content
Thursday 19 February 2026
BlueSky linkedin youtube
header links
  • Get Newsletters
  • Media Kit
Home
Pharmaphorum menu first category
  • News
  • Views & Analysis
  • Deep Dive
    • Equity and Sustainability
    • Research & Development
    • Market Access
    • Oncology
    • Artificial Intelligence
    • Patients & Partnerships
    • Previous Editions
  • Webinars
  • Podcasts
  • Videos
  • Spotlight on
    • ASCO 2025
    • BIO 2025
    • C-Suite Innovators
    • ESMO 2025
    • Frontiers Health 2025
    • JP Morgan
    • Global Policy Insights
  • Events
Pharmaphorum
close
    SECTION
    • News
    • Views & Analysis
    • Deep Dive
      • Research & Development
      • Market Access
      • Oncology
      • Artificial Intelligence
      • Patients & Partnerships
      • Commercialisation
      • Previous Editions
    • Webinars
    • Podcasts
    • Videos
    • White Papers
    • Events
Channels
    Channels
    • Sales & Marketing
    • R&D
    • Digital
    • Market Access
    • Oncology
    • Patients
    • Spotlight On
Channels
  • Sales & Marketing
  • R&D
  • Digital
  • Market Access
  • Oncology
  • Patients
  • Spotlight On
    SUB NAVIGATION
    • Live Coverage
    • Partner Content
    • About us
    • Work for us
    • Contribute
    • Contact us
    • Advertise

Newsletters and Deep Dive digital magazine

 
 
Sign up
youtube linkedin BlueSky
Sign in

Oncology

News
Imfinzi1

Finally, AZ claims a win with Imfinzi/tremelimumab cancer co...

News
Shanghai at night, China

OnQuality Pharma raises $15m for drug to treat VEGF side eff...

Events
PharmaPhorum Banner
Partner Content

4th Annual PREDiCT Tumor Models San Francisco

Serving the immuno-oncology scientific community

News
AZ’s new cancer drugs drive another stellar quarter

AZ’s new cancer drugs drive another stellar quarter

News
OpdivoLarge

BMS gets a much-needed win with Opdivo in first-line lung ca...

News
Gilead_yescarta_production

Scotland says ‘yes’ to Gilead’s CAR-T Yescarta for lymphoma

  • Load more results

Editor's Picks

  1. Hudson out at Sanofi, as Belén Garijo named CEO
  2. Lilly strikes $8.8bn-plus alliance with China's Innovent
  3. Euro VCs team up to invigorate life sciences ecosystem
  4. Moderna cries foul as FDA blocks filing of mRNA flu shot
  5. Novo Nordisk rises as Hims & Hers backs down on oral GLP-1
News
Hims & Hers logo on blue atlas background

Hims & Hers buys Australian digital health firm for $1.15bn

Hims & Hers, facing a threat to its compounded medicines business, has ramped up its push for international expansion by buying Eucalyptus Health.

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png
Sales & Marketing
Physicians walking and using tablet devices
Sponsored

How to meet your physicians where they are online

A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.

Pharmaphorum Menu
  • Digital
    • News
    • Views & Analysis
    • Deep Dive
    • Webinars
    • Podcasts
    • Video
    • White Papers
    • Event
  • Market Access
    • News
    • Views & Analysis
    • Deep Dive
    • Webinars
    • Podcasts
    • Video
    • White Papers
    • Event
  • Oncology
    • News
    • Views & Analysis
    • Deep Dive
    • Webinars
    • Podcasts
    • Video
    • White Papers
    • Event
  • Patients
    • News
    • Views & Analysis
    • Deep Dive
    • Webinars
    • Podcasts
    • Video
    • White Papers
    • Event
  • R&D
    • News
    • Views & Analysis
    • Deep Dive
    • Webinars
    • Podcasts
    • Video
    • White Papers
    • Event
  • Sales & Marketing
    • News
    • Views & Analysis
    • Deep Dive
    • Webinars
    • Podcasts
    • Video
    • White Papers
    • Event
  • Spotlight on
    • Axtria Ignite 2025
    • Frontiers Health 2024
    • Life Science Industry Report
    • World Without Disease Summit

Sign up for email newsletters and Deep Dive

Get Newsletters

 
 
youtube linkedin BlueSky
Pharmaphorum
About us Advertising Contact us
Contribute Cookie Policy Privacy Policy
Terms & Conditions Work for us
The rights of trademark owners are acknowledged. Website and content copyright © 2009-2026, pharmaphorum media limited or its licensors; all rights reserved. pharmaphorum – an EVERSANA company
The rights of trademark owners are acknowledged. Website and content copyright © 2009-2026, pharmaphorum media limited or its licensors; all rights reserved. pharmaphorum – an EVERSANA company